Novel platelet aggregation inhibitor for the treatment and prophylaxis of cardiovascular diseases
The aim of the portrayed invention is to develop and make new drugs for the primary- and secondary prophylaxis of thrombosis complications as well as the general treatment of cardiovascular diseases available, using inhibitors of the multidrug resistance protein (MRP) in human platelets, more specifically of MRP4.
Further Information: PDF
PVA Mecklenburg-Vorpommern AG
Phone: +49 (0)381/49 74 74 0
Contact
Antonio Martinez
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Parallel Paths: Understanding Malaria Resistance in Chimpanzees and Humans
The closest relatives of humans adapt genetically to habitats and infections Survival of the Fittest: Genetic Adaptations Uncovered in Chimpanzees Görlitz, 10.01.2025. Chimpanzees have genetic adaptations that help them survive…
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…